Investing

PepGen : PEPG

PEPG

Stock Data

$5.50

$0.16 (2.85%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

PepGen Inc. is a pioneering biotechnology firm based in Boston, Massachusetts, dedicated to advancing the treatment of severe neuromuscular and neurologic diseases. With a focus on oligonucleotide therapeutics, its flagship product, PGN-EDO51, is currently undergoing Phase I clinical trials aimed at combating Duchenne muscular dystrophy. Additionally, PepGen is exploring treatments for myotonic dystrophy type 1 and other forms of muscular dystrophy, demonstrating its commitment to addressing unmet medical needs in the neuromuscular field since its inception in 2018.

All PepGen Articles

2 Articles

Trey Thoelcke | Oct 7, 2025 at 8:45 AM EDT

Insiders Snap Up $54M in Biotech and Offshore Driller Stocks

In the past week or so, some public offerings prompted huge insider buying. However, these were not the only notable…

Trey Thoelcke | Feb 18, 2024 at 11:20 AM EST

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted…